Supported by one trial
One controlled phase 3 trial met its main goal. Confirmed needs a second trial or regulatory approval for this use.
Immune reconstitution (cladribine, alemtuzumab, aHSCT): prevent or delay MS in early MS (CIS or RIS)
early MS (CIS or RIS) · Immune reconstitution (cladribine, alemtuzumab, aHSCT)
One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 617
How the verdict was reached
Supported in phase 3: One controlled phase 3 trial met its main goal. Confirmed needs a second trial or regulatory approval for this use.
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| ORACLE MS | Phase 3 | 617 | 2008 | Met its main goal | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Nov 2026Status changed from Confirmed to Supported by one trial
- Oct 2026First listed as Confirmed
Related hypotheses
Assembled by software from public sources.